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SUMMARY

Cancer develops after the acquisition of a collection
of mutations that together create the cancer phenotype. How collections of mutations work together
within a cell and whether there is selection for certain
combinations of mutations are not well understood.
We investigated this problem with a mathematical
model of the Ras signaling network, including a
computational random mutagenesis. Modeling and
subsequent experiments revealed that mutations of
the tumor suppressor gene NF1 can amplify the effects of other Ras pathway mutations, including
weakly activating, noncanonical Ras mutants.
Furthermore, analyzing recently available, large, cancer genomic data sets uncovered increased cooccurrence of NF1 mutations with mutations in other
Ras network genes. Overall, these data suggest that
combinations of Ras pathway mutations could serve
the role of cancer ‘‘driver.’’ More generally, this work
suggests that mutations that result in network instability may promote cancer in a manner analogous to
genomic instability.
INTRODUCTION
Cancer genomic studies support the idea that a cell becomes
cancerous through the progressive acquisition of mutations
that together confer the cancer phenotype. These mutations
that promote cancer are commonly referred to as ‘‘driver genes’’
(Stratton et al., 2009). It is not well understood how the presence
of one mutation influences the selection of subsequent mutations
through an evolutionary process (Yates and Campbell, 2012). A
statistical lack of co-occurrence between ‘‘canonical’’ mutations
within the same pathway is well established (Thomas et al., 2007;
Yates and Campbell, 2012). The lack of co-occurrence is typically
attributed to the assumption that there would be no selective
benefit to accumulating multiple mutations within the same mo-

lecular pathway (Yeang et al., 2008). Such arguments implicitly
assume that each mutation is sufficiently strong to confer a selective advantage alone (e.g., the canonical KRAS and BRAF mutations). However, there are a number of weakly activating RAS and
BRAF mutations that have been observed in cancer (Wan et al.,
2004), although less commonly than the canonical mutations.
It is believed that many cancers share common phenotypes,
such as constitutive activation of the Ras pathway (Hanahan
and Weinberg, 2000). Within some types of cancer, there is
near universal presence of a mutation that confers this phenotype
to the Ras pathway. For example, essentially all sequenced pancreatic adenocarcinomas have canonical KRAS mutations (Biankin et al., 2012; Jones et al., 2008), and essentially all hairy cell
leukemias have the canonical BRAF V600E mutation (Tiacci
et al., 2011). More commonly, a type of cancer can utilize one
of several potential gene mutations. Melanomas, for example,
frequently harbor either a canonical BRAF or a canonical NRAS
mutation (Hodis et al., 2012). When a canonical driver mutation
is not identified in a sequenced cancer, other candidate driver
mutations are often proposed based upon the identification of a
mutated gene within the same pathway as a common, canonical,
driver mutation (Hodis et al., 2012; Jones et al., 2008). Whether or
not these less common ‘‘noncanonical’’ mutations, which are
often less strongly activating than the canonical mutations, are
sufficient to serve as a surrogate for a canonical driver mutation,
or whether the ability to serve as a surrogate is conditional to
some other contextual influence, is not fully understood. The
role of noncanonical mutants in cancer is quite important when
one considers the growing number of cancers that are being genomically characterized for both research and clinical purposes.
We investigated the potential for cooperation between less
commonly mutated genes within the Ras network. We used a
mathematical model to investigate whether canonical and noncanonical Ras mutants are influenced by the partial loss of tumor
suppressor gene product neurofibromin (NF1). We found computational evidence for greater-than-additive increases in Ras
activation for noncanonical Ras mutants in the neurofibromindeficient context. This prediction was also supported experimentally in cells with or without neurofibromin. Further, analyzing
>3,900 sequenced cancer specimens from the Cancer Cell Line
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Encyclopedia (CCLE) and The Cancer Genome Atlas (TCGA) uncovered an increased rate of co-occurrence between mutations
the model predicted could display synergy. This work suggests
that NF1 mutations promote cancer not only by the direct
and immediate increase in RasGTP but also by increasing the
number of possible subsequent mutations that would further increase Ras signaling. This suggests that multiple, weakly activating mutations may together serve the role of driver gene.
Generalization of the ‘‘network instability’’ concept as presented
here to cancer treatment suggests that a wide variety of mutations could confer resistance to targeted therapies. Overall,
this work demonstrates that a biochemical/mechanistic understanding of cell-signaling networks can be used to uncover functional combinations of mutations.
RESULTS
Modeling Predicts Synergy between Weakly Activating
Ras Pathway Mutants
We previously developed a mathematical model based upon the
biochemical reactions for the major classes of proteins that regulate Ras guanosine triphosphatase (GTPase) signaling (Stites
et al., 2007). We evaluated how well our Ras model applied to
neurofibromin-deficient conditions, and we found that the model
robustly reproduces common phenotypes of neurofibromindeficient systems (Figure S1A; Supplemental Experimental
Procedures). We used this model to investigate the effect of concurrent Ras and neurofibromin mutations. We initially considered
the canonical, oncogenic Ras mutants RasG12D and RasG12V
and the noncanonical, weakly activating RasF28L mutant.
When neurofibromin is fully present and not mutated, RasF28L
was predicted to result in approximately half the RasGTP signal
as RasG12D or RasG12V, which is consistent with experimental
data for these mutants (Stites et al., 2007). However, when we
modeled RasF28L in the neurofibromin-deficient context, we
observed that RasF28L generated a high level of Ras activation
similar to the strong RasG12D and RasG12V mutants (Figure 1A,
top). This is due, in part, to a less-than-additive increase in Ras
signals when RasG12D and RasG12V are combined with neurofibromin deficiency (Figure 1A, bottom). This less-than-additive
increase may be consistent with the general lack of co-occurrence between commonly observed ‘‘strong’’ mutations in that
it suggests there is a small benefit to acquiring a second strong
mutation. Interestingly, RasF28L exhibited a greater-than-additive increase in Ras signals when combined with a loss of neurofibromin activity. We hypothesized that there may be a large
number of such ‘‘inherently weaker’’ Ras mutants beyond
RasF28L that would result in high levels of Ras pathway activation in the neurofibromin-deficient (NF1-deficient) conditions,
but not in neurofibromin wild-type (NF1-WT) conditions.
Computational Mutagenesis Predicts that Some Weak
Ras Mutants Could Become Strong in a NeurofibrominDeficient Context
Very few Ras mutants have been characterized as extensively as
RasG12D and RasG12V. We therefore performed a ‘‘computational random mutagenesis’’ to more comprehensively explore
the possible extent to which neurofibromin deficiency might
308 Cell Reports 10, 307–316, January 20, 2015 ª2015 The Authors

affect potential Ras mutants (Supplemental Experimental Procedures). By varying the biochemical rate constants and enzymatic
parameters that characterize a Ras protein, we can model potential Ras mutants. We simulated one million such random mutants and compared the Ras signal levels (both RasGTP and
effector:RasGTP complex) in the context of both the NF1-WT
and NF1-deficient networks.
We analyzed the relative frequencies with which these
randomly generated Ras mutants achieved different RasGTP
levels (Figure 1B). In the NF1-WT context, most mutants did
not cause a large increase in Ras signaling. A long, shallow tail
of more strongly activating mutants was present. This suggests
that there are a limited number of potential Ras mutations that
result in high levels of ‘‘constitutive’’ Ras activation and are
strong enough to promote cancer by themselves. In contrast,
in the NF1-deficient context, the distribution was shifted toward
higher levels of RasGTP, and the relative frequencies of mutants
generating higher levels of RasGTP were increased. This suggests that the number of potential Ras point mutations capable
of promoting cancer may be greater in the NF1-deficient context.
We then examined how the level of RasGTP for each mutant
differed between NF1-WT and NF1-deficient contexts, and we
considered the potential synergy between neurofibromin and
Ras mutants (Figure 1C). Approximately 13% of all random mutants displayed greater-than-additive increase in RasGTP under
neurofibromin deficiency. We then arbitrarily focused on mutants
that resulted in 25% of total Ras bound to GTP, because 25%
of cellular RasGTP has been shown to approximate where transformation potential abruptly begins (Donovan et al., 2002). We
found that 15% of all random mutants exceeded this 25% level
of RasGTP in the NF1-deficient context, but not in the NF1-WT
context. Analysis of other threshold levels of RasGTP similarly
revealed large fractions of random mutants that exceed the
threshold in NF1-deficient, but not NF1-WT, conditions (Figure S1B). Similar results were found when we considered the
quantity of effector:RasGTP complex as an alternative measure
of Ras activation (Figure S1C). Consideration of the computational random mutants that fell within the different quadrants of
Figure 1C found considerable overlap in mutant parameter
values, suggesting that the behaviors of a newly identified Ras
mutant cannot be easily inferred from any single parameter measurement (Figure S1D). Overall, these simulations suggest that
the strength of a mutant can be context dependent; a Ras mutant
that appears ‘‘weak’’ in a wild-type background may appear
‘‘strong’’ in an NF1-deficient background. The model also predicts that the number of Ras mutants that could result in a high
level of RasGTP will be increased in NF1-deficient conditions.
We highlight that these results are for modeling a loss of neurofibromin GAP activity, such as might occur from a deletion mutation or from a nonsense mutation (Stratton et al., 2009). Deletion
mutations and truncation mutations before the GAP domain are
observed in human cancers (Cancer Genome Atlas Research
Network, 2008). Missense point mutations are also observed
for NF1, and missense mutations can result in a GAP domain
with altered biochemistry (Sermon et al., 1998). We considered
whether point mutants with impaired GAP activity would exhibit
similar behaviors when combined with Ras mutations. Simulations of neurofibromin R1276A point mutant were performed
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Figure 1. Modeling Predicts that Weakly Activating Ras Mutants Can Appear Strong within the NF1-Deficient Context
(A) Top: simulations of the Ras network model with all wild-type Ras, a canonical oncogenic mutant (RasG12D and RasG12V), or a noncanonical, nononcogenic
mutant (RasF28L) for both NF1-WT and NF1-deficient conditions. Bottom: the net change in predicted RasGTP levels going from NF1-WT to NF1-deficient
conditions for the cases above.
(B) Histogram from our ‘‘computational mutagenesis’’ displaying the number of Ras mutants with varying levels of RasGTP signal in the context of NF1-WT (blue)
and NF1-deficient (red) conditions. Dashed black line shows level of RasGTP for a network with all RasWT (no mutation present); dashed brown line shows level of
RasGTP for a network with a RasG12V mutation. Histogram is binned into 0.1% intervals.
(C) One million random mutants were simulated in the NF1-WT and NF1-deficient states, and the resulting levels of RasGTP are plotted for both conditions. Filled
circles indicate a network containing a Ras mutant: RasG12D (black); RasG12V (white); RasF28L (red); or no Ras mutant (yellow). Green lines indicate 25% total
RasGTP. Any random Ras mutant falling above the dashed gold line shows a greater net change in percent RasGTP in the NF1-deficient network compared to the
NF1-WT network.

by using measured changes to its kcat and Km. We simulated this
missense mutant in combination with specific Ras mutants and
with computational random Ras mutants, just as we had done
for neurofibromin deficiency. In our simulations of the neurofibromin point mutant, we similarly observed a greater-than-additive

increase in signal strength when combined with RasF28L, similarly observed a sizable proportion of greater-than-additive
computational random Ras mutants, and similarly observed a
large fraction of mutants that exceeded a given level of RasGTP
only in the NF1 mutant conditions (Figure S1E). Together, these
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Figure 2. Weak Ras Mutants in Mammalian Cells Can Behave as Strong Activators of Ras Pathway Signaling under the Nf1-Deficient
Conditions
(A) Immunoblots of Nf1+/+, Nf1+/, and Nf1/ mouse embryo fibroblasts (MEFs) for expression of neurofibromin, p120 Ras GAP, and phosphorylated ERK.
(B) MEFs of the Nf1+/+, Nf1+/, and Nf1/ genotype were analyzed by qPCR for Ras GAP genes Rasa1 (p120GAP), Rasa4 (CAPRI), DAB2IP, and Nf1. Error
bars represent SD from three independent experiments from three different RNA extractions/preparations.
(C) Left: histograms present pERK profiles within Nf1+/+, Nf1+/, and Nf1/ MEF cells. Data presented are representative of at least six similar experiments
(right).
(D) Nf1+/+ and Nf1/ MEFs transfected with HA-tagged H-RasWT, H-RasF28L, or H-RasG12D with HA-tag expression and pERK signal quantified by
multicolor flow cytometry. a.u., arbitrary units.
(E) Immunoblots showing expression of HA-tagged H-RasF28L and V5-tagged NF1-GRD in Nf1/ and Nf1+/+ MEF cells following transfection, either alone or
together.
(F) MEFs transfected with HA-tagged H-RasF28L or with HA-tagged H-RasF28L and NF1-GRD with HA-tag expression and pERK signal quantified by multicolor
flow cytometry. Nf1(/) + F28L, red; Nf1(/) + F28L + NF1-GRD, green; Nf1(+/+) + F28L, blue; Nf1(+/+) + F28L + NF1-GRD, black. Solid, higher HA; dashed,
lower HA.

simulations suggest that a wide variety of NF1 mutations should
create a context that amplifies the effects of noncanonical Ras
mutants.
RasF28L Mutant Is More Strongly Activating in the
Neurofibromin-Deficient Cellular Context
We next experimentally tested our computational prediction that
some weak Ras mutants will more strongly activate the Ras
pathway within the NF1-deficient context. We obtained mouse
embryo fibroblasts (MEFs) that had been previously derived
from Nf1-deficient, wild-type, and heterozygous null mice
(Nf1/, Nf1+/+, and Nf1+/, respectively; Shapira et al.,
2007). We confirmed that the Nf1+/ and Nf1/ MEFs had
decreased protein expression (Figure 2A) and decreased
310 Cell Reports 10, 307–316, January 20, 2015 ª2015 The Authors

mRNA expression for NF1 (Figure 2B). Within the MEFs, we
noted increased expression of RNA and protein for some Ras
GAPs (Figures 2B and 2C), which is consistent with negative
feedback resulting from increased Ras signaling. Negative feedback induced by Ras pathway activation has important physiologically consequences, including a role in senescence (Courtois-Cox et al., 2006) and in resistance to targeted therapies
(Prahallad et al., 2012). However, levels of phosphorylated ERK
(pERK) by western blot (Figure 2A) and by flow cytometry (Figure 2C) reflected the different levels of neurofibromin deficiency.
Moreover, when we tested proliferation of these MEFs in a time
course using the CellTrace Violet dye (whose fluorescence dilutes by half in daughter cells), we observed enhanced level of
proliferation in neurofibromin-deficient MEFs compared to the

control MEFs (Figure S2). These data are consistent with previous results for these MEFs (Shapira et al., 2007) and suggest
that any negative feedback present in these cells is unable to
overcome the anticipated phenotypic consequences of elevated
Ras pathway signaling. Altogether, these observations suggest
that neurofibromin plays a critical and dominant role in these
MEF cells. We conclude that these MEFs could be used for our
further analysis.
We next examined how variation in the level of RasF28L expressed could affect ERK phosphorylation in Nf1+/+ and Nf1/
conditions. We transiently transfected hemagglutinin (HA)tagged H-RasF28L, H-RasG12D, or H-RasWT into Nf1+/+ and
Nf1/ MEFs. Flow cytometry was used to obtain quantitative
measurements of both the amount of transfected protein expression at a single cell level and the amount of resulting Ras pathway
activation within each cell. These measurements showed that
RasF28L expression caused a higher level of phosphorylated
ERK signal in Nf1/ MEFs than in Nf1+/+ MEFs (Figure 2D).
Furthermore, gating the RasF28L cells based on relatively lower
and relatively higher expression demonstrated that the change in
ERK phosphorylation for increased RasF28L expression was
concomitantly enhanced in the Nf1/ MEFs relative to the
Nf1+/+ MEFs, consistent with the model predictions. We quantified the ratio of change in mean pERK signal between the high
and low HA gates and found that the increase in pERK was 1.9
times higher for RasF28L in Nf1/ MEFs compared to Nf1+/+
MEFs. In contrast, RasG12D cells experienced a smaller increase going from low to high expression between Nf1+/+
and Nf1/ MEFs (with the ratio of change quantified at 1.1).
The ratio for RasWT was in between that of RasF28L and
RasG12D (1.43).
If the greater changes in phosphorylated ERK within Nf1/
conditions were due to the loss of GAP activity by neurofibromin,
then reintroduction of neurofibromin would be expected to
reverse the increased change. We expressed the GAP-related
domain of neurofibromin (NF1-GRD), as this domain alone is sufficient to catalyze the hydrolysis of GTP on Ras. We cotransfected Nf1/ and Nf1+/+ MEFs with HA-tagged RasF28L and
with V5-tagged NF1-GRD (Figure 2E). The flow-cytometrybased ERK activation assay revealed that coexpression of
NF1-GRD reversed the large magnitude changes in pERK due
to RasF28L expression in Nf1/ MEFs (Figure 2F, top). Furthermore, coexpression of NF1-GRD with RasF28L in Nf1+/+ MEFs
had a similar but smaller effect on changing the phosphorylated
ERK signal as a function of RasF28L (Figure 2F, bottom). Overall,
these experimental observations support the important and
nonobvious prediction from the mathematical model that neurofibromin deficiency can cause some normally weak Ras mutants
to have a stronger effect on Ras pathway activation.
Instability of the Ras Signaling Network in the Context of
Neurofibromin Deficiency
We next investigated why GAP-deficient conditions might
augment the effects of some Ras mutations. We hypothesized
that the sensitivity of the NF1-WT and NF1-deficient Ras networks might be differentially affected by changes in Ras
biochemistry. Our Ras model includes the five basic processes
that regulate the nucleotide-binding state of Ras proteins: GAP

activity on Ras; GEF activity on Ras; intrinsic GTPase activity;
spontaneous nucleotide dissociation and association; and
GTP-bound Ras interactions with effector proteins (Figure 3A).
Each of these processes is modeled with mass-action kinetics
or enzymatic kinetics and described with the parameters listed
in Figure 3A. We considered the magnitude of change in total
RasGTP that would result for a wide range of changes in each
parameter when it occurs in NF1-WT and in NF1-deficient conditions (Figures 3B, S3A, and S3B). Such a sensitivity analysis
approach has been valuable in a wide variety of modeling studies
(Benedict et al., 2011; Chen et al., 2014; Gaudet et al., 2012;
Schoeberl et al., 2002; Stites et al., 2007).
When we considered the amount of RasGTP that results from
a change in a single reaction parameter, our sensitivity analysis
found qualitatively similar results for NF1-WT and NF1-deficient
networks. It was notable, however, that the magnitude of change
in RasGTP for a small change in a parameter was always greater
for the NF1-deficient network (Figures 3B, S3A, and S3B). This
was true for all 17 of the model’s biochemical properties (p < 1.6
3 105 by the two-tail exact binomial test).
To further investigate the relevance of this observation, we
analytically solved for the change in total RasGTP for a change
in parameter (v Total RasGTP=v parameter) for both NF1-WT
and NF1-deficient networks (i.e., we found the slope of the
curves relating steady-state RasGTP to parameter values taken
through the point corresponding to the baseline Ras network parameters). As inferred from the graphical relationship, the analytical approach revealed that the net change in RasGTP induced
by a small parameter change is higher in the NF1-deficient
network (Figure 3C). Indeed, the NF1-deficient network was
often 10–100 times more sensitive to the same change in a network reaction rate constant and/or protein concentration (Figure 3D). Thus, any small perturbation to the Ras network should
cause a larger magnitude change in Ras signal if the network is
also NF1 deficient. The increased sensitivity is robust to the level
of GAP deficiency considered (Figure S3C) and to the concentrations of Ras network proteins modeled (Figure S3D). This
suggests that the predicted increased sensitivity of neurofibromin-deficient cells could occur in a wide variety of cell types,
regardless of specific levels of protein expression and of specific
levels of neurofibromin deficiency.
Instability of the Ras Signaling Network in the Context of
GAP and GEF Deregulation
Because GAPs and GEFs have opposite effects on Ras, we
considered the possibility that partial activation of Ras GEFs
will be analogous to partial loss of Ras GAPs. Our computational
random mutagenesis found that increased basal GEF activity
(such as what might follow from an upstream mutation or from
a Ras GEF mutation) could also potentiate the effects of some
(but not all) Ras mutants (Figure S3E), similar to what we found
for neurofibromin in Figure 1. We also performed a sensitivity
analysis for increased basal Ras GEF activity like we did for neurofibromin deficiency in Figure 3C. We found that increased
basal GEF activity also makes the Ras network more sensitive
to perturbations (Figure S3F). That is, increased sensitivity
to perturbations should be a more-general feature of cells
harboring Ras GAP and Ras GEF mutations.
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Figure 3. Mathematical Model of the Ras Network Predicts the NF1-Deficient Ras Network Is Generally More Sensitive to Perturbations
(A) The components of the Ras network considered are Ras, Ras GEFs, Ras GAPs, and Ras effectors, along with the modeled reactions and their biochemical
parameters.
(B) Sample steady-state RasGTP and net change in steady-state RasGTP levels for a range of fold changes in model parameters. Ras expression level is shown
here; all parameters are presented in Figure S3. DRasGTP levels are normalized to the total amount of Ras.
(C) The magnitude of the immediate rate of change in RasGTP for a change in parameter is a measure of the sensitivity of the Ras network to that parameter.
(D) The ratio of the sensitivities determined in (C).
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Co-occurrence between NF1 Mutations and
Noncanonical Ras Mutations in Cancer Genomic
Data Sets
Although strongly activated, canonical Ras pathway mutations
(like KRAS and BRAF mutations) are known to co-occur much
less than would be expected from their individual frequencies,
much less is known about the co-occurrence patterns of the
much less frequently mutated genes in the Ras network. As noncanonical RAS mutations are much less commonly observed
than canonical RAS mutations, an analysis of increased cooccurrence requires a large data set. We first considered the
CCLE, which includes massively parallel sequencing data for
greater than 900 cancer cell lines (Barretina et al., 2012). We
considered the mutations to KRAS, NRAS, HRAS, and NF1
within this data set (Table S1). We investigated the frequency
with which NF1 mutations co-occurred with noncanonical RAS
mutations (i.e., KRAS, NRAS, and HRAS mutations that are not
at codon 12, 13, or 61) and with canonical RAS mutations (codon
12, 13, or 61; Figure 4A). Within the population of cancer cells
containing a canonical KRAS mutation, NF1 mutations occurred
at a rate similar to their 9% overall rate of occurrence in this data
set. In contrast, 31% of cell lines containing noncanonical KRAS
mutations also had an NF1 mutation (p < 0.005). Within this data
set, we note that BRAF V600E and canonical KRAS mutations
tend not to co-occur (p < 0.0001).
Next, we analyzed the recently published data set from TCGA,
which included sequencing for more than 3,000 different human
cancer samples (Kandoth et al., 2013). Noncanonical KRAS,
NRAS, and HRAS mutations were found to co-occur much
more frequently with an NF1 mutation (Figure 4B; Table S2).
The increase was statistically significant for KRAS (p < 0.004)
and NRAS (p < 0.02). The rate of NF1 mutation in cancers with
a noncanonical KRAS mutation (22%) was higher than the overall
5% rate of mutation for NF1 in the entire data set and higher than
the 4% rate of NF1 mutation in cancers with a canonical KRAS
mutation. Of note, within this TCGA data set, there was no
apparent trend for or against co-occurrence of canonical
KRAS mutations with the BRAF V600E mutation.
Within both data sets, both canonical and noncanonical
KRAS mutations co-occurred with TP53 mutations at similar
rates (Figure S4A). Rates of TP53 mutations were not significantly different between NF1 mutant and NF1 WT samples
for the CCLE and for the TCGA data (Figure S4B). Many of
the NF1 mutations observed in cancer samples have also
been observed in patients with neurofibromatosis (Table S3),
which demonstrates a clear functional consequence for these
NF1 mutations. The overall numbers of mutations per sample
for cancers containing noncanonical KRAS mutations or canonical KRAS mutations were not significantly different (Figure S4C). Co-occurrences with an NF1 mutation were more
likely to be observed in samples with a higher number of mutations reported for both canonical (p = 0.025) and noncanonical
(p = 0.0047) KRAS mutations (Figure S4D; p values by the
Mann-Whitney test). Overall, the increased co-occurrence of
NF1 mutations with noncanonical RAS mutations is consistent
with our prediction that a large fraction of less-potent RAS mutations cause strong Ras pathway activation if they co-occur
with an NF1 mutation.

Noncanonical Ras Mutations Commonly Co-occur with
Ras GAP and Ras GEF Mutations
We considered noncanonical KRAS mutations for co-occurrence with non-NF1 Ras GAP mutations and with Ras GEF mutations. Within both the CCLE and TCGA data, we find increased
rates of co-occurrence between Ras GAPs and noncanonical
KRAS mutations (Figure S4E). We also find increased rates of
co-occurrence between Ras GEFs and noncanonical KRAS mutations in both the CCLE and TCGA data (Figure S4F). Overall,
noncanonical KRAS mutations co-occurred with at least one
Ras GAP or Ras GEF mutation approximately twice as often as
canonical KRAS mutations in both the CCLE and TCGA data
(Figure 4C). The trend for an increased rate of GAP or GEF mutations with noncanonical KRAS mutations in the combined
data set was highly significant (p < 0.005 by Fisher’s exact
test). Overall, the increased co-occurrence between noncanonical RAS mutations and Ras GAP or Ras GEF mutations is
consistent with our computational-model-based prediction that
Ras GAP and Ras GEF mutations can synergize with some
weakly activating Ras mutations.
General Increase in Co-occurrence of Ras Pathway
Mutations in Cancer Genomes
We hypothesized that the increased sensitivity to perturbation
should also result in an increased co-occurrence of NF1 mutations with mutations to the genes of Ras network proteins
(GEFs, GAPs, and effectors). Within the CCLE data, the frequency of Ras network mutations appeared higher for NF1
mutant cells than for NF1 wild-type cells (Figure 4D). The increased co-occurrence was statistically significant for Ras effectors PIK3CA and ARAF, as well as for upstream EGFR mutations
and for several Ras GAPs and Ras GEFs. Within the larger TCGA
data set, we also found a trend for increased co-occurrence of
NF1 mutations with less commonly mutated Ras pathway genes
(Figure 4E). Of note, we found increased rates of co-occurrence
between NF1 mutations and noncanonical Ras effector mutations, RAF1, ARAF, and RALGDS, as well as with multiple other
Ras GAPs and Ras GEFs.
DISCUSSION
It has been argued that better methods are needed for
analyzing the relationship between mutations and the perturbed cell-signaling networks that drive cancer (Yaffe, 2013).
We have presented here the use of mass-action modeling to
uncover previously unappreciated relationships between pairs
of mutations. Our model was based on the traditional understanding of Ras network biochemistry and the available, quantitative measurements that characterize Ras network biochemistry. Model predictions have been prospectively validated
experimentally in mammalian cells. Importantly, insights gained
from these computational and experimental studies generated
specific hypotheses that we could test in existing, large, cancer
genomic data sets. Such an approach should be more generally
applicable to other signaling networks.
The finding that the Ras network with a weakly activating mutation is generally more sensitive to subsequent perturbations
has important implications in cancer development. The cancer
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Figure 4. Co-occurrence of Noncanonical Ras Mutants with NF1, Ras GAP, and Ras GEF Mutants
(A and B) Percentage of canonical and noncanonical KRAS, NRAS, and HRAS mutants that co-occur with an NF1 mutation (A) within the CCLE data set (Barretina
et al., 2012) or (B) within the TCGA data set (Kandoth et al., 2013).
(C) Percentage of canonical and noncanonical KRAS mutant samples from the CCLE and TCGA that also harbor at least one GAP or GEF mutant.
(D) Mutation frequency for Ras network genes within NF1 mutant and NF1 WT subsets of the CCLE data set (Barretina et al., 2012).
(E) Mutation frequency for Ras network genes within NF1 mutant and NF1 WT subsets of the TCGA data set (Kandoth et al., 2013).
N.S., not significant. The p value for all panels is by Fisher’s exact test.
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phenotype results from the acquisition of multiple somatic
mutations that ultimately result in altered levels of protein
expression (including complete loss of expression) and/or the
expression of a protein with altered biochemistry (Stratton
et al., 2009). The computational-model-based predictions and
experimental work presented here suggest that the number of
biochemical perturbations (and causal genetic aberrations)
with a large effect on Ras pathway signal increases in the context of neurofibromin deficiency. This would expand the number
of potential driver genes that promote cancer in the neurofibromin-deficient context. The net rate of acquiring a cancer-promoting mutation is proportional to both the rate of mutation
and the proportion of mutations that offer a selective advantage
to the cell. Genetic instability is a common feature of cancer
that results in an increased rate of mutations that could promote tumorigenesis (Beckman and Loeb, 2005). Our work suggests an alternative, yet complementary mechanism of network
instability that results in an increased net rate of acquiring cancer-promoting mutations through the acquisition of a state
where a greater proportion of mutations would offer a selective
advantage.
The concept of network instability as demonstrated here could
also have important implications for the treatment of diseases.
Targeted therapies against a cancer oncogene function by inhibiting the signal produced by the oncogene. If the patterns of
instability observed for Ras (e.g., Figure S3C) are more general
for other signaling proteins, it would suggest that partial reduction of signal may result in a network that remains unstable in
the sense that the effects of other mutations are amplified. This
instability would enable a wide variety of potential mutations to
restore activation of the targeted pathway. This consequence
of network instability is consistent with patterns of resistance
to targeted therapies. For example, it has been shown that
BRAFV600E cells being treated with vemurafenib can become
resistant through increased COT expression (Johannessen
et al., 2010). COT is mitogen-activated protein kinase kinase kinase, like BRAF, but it has rarely been observed mutated in cancers. The increased importance of a gene mutation that is not
commonly associated with the cancer is consistent with the
concept of network instability. Of note, one of the commonly
found mechanisms for resistance to vemurafenib is loss of neurofibromin function (Maertens et al., 2013; Shalem et al., 2014;
Whittaker et al., 2013). Those findings further highlight the role
of NF1 mutations as promoters of network instability that amplify
the consequences of other Ras pathway mutations.

Flow Cytometry
Immortalized Nf1+/+, Nf1+/, and Nf1/ MEF cells were transiently transfected with plasmid constructs using Lipofectamine (Invitrogen). Cells were
starved for 12 hr before cytometry analysis. MEF cell staining for phosphoErk1/Erk2 (referred to as phospho-ERK or pERK) and HA-tagged H-Ras was
performed as described previously (Stites et al., 2007). Data were acquired
on a FACS CantoII (Becton Dickinson). Cells were gated based on the intensity
of the HA signal to define ‘‘high-’’ and ‘‘low-’’ HA-expressing populations. The
same intensity gates were used for comparisons between Nf1+/+ and Nf1/
MEFs, as well as between cells transfected with different Ras constructs. Mean
pERK intensity was quantified for high and low HA expression, and the ratio of
differences between high and low HA expression, ratio = ðHAhigh ðNf1= Þ
HAlow ðNf1= ÞÞ=ðHAhigh ðNf1 + = + Þ  HAlow ðNf1 + = + ÞÞ; was used as a measure
of the change in sensitivity between Nf1/ and Nf1+/+ conditions.
Genomic Analysis
Mutations for the genes of Ras network proteins were obtained from the CCLE
portal (http://www.broadinstitute.org/ccle/home) and/or from published cancer genome publications (Barretina et al., 2012; Kandoth et al., 2013). Exonic
missense and nonsense mutation and exonic insertions and deletions were
considered. The mutations considered from the CCLE and TCGA are listed
in Tables S1 and S2. Fisher’s exact test was used to determine p values for
co-occurring mutations. Calculations were performed in R version 2.13.0.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.12.035.
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